Abstract:Purpose: In this study, we empirically investigate the impact of the COVID-19 pandemic on China's stock price volatility during and after its initial outbreak, using time-series daily data covering the period from July to October, 2020 and 2021, respectively. Design/Methodology/Approach: In the estimation, the ARDL bounds test approach was employed to examine the existence of co-integration and the relationship of long-run and short-run between the new infection rates and stock price volatility, as stable and unstable variables are mixed. The inner-day and inter-day volatility, based on the Shanghai (securities) composite index, are estimated in separate empirical models. In addition, the Inter-bank overnight lending rate (IBOLR) is controlled in order to consider the effect of liquidity and investment cost. Findings and Implications: We find that in the initial year (2020) of the epidemic, the new infection rate is negatively correlated to stock prices in the short-term, whereas no significant evidence existed in the long-term, regardless of model specifications. However, after the epidemic's outbreak (2021), the result depicts that new infections increased stock prices in the long-term, and depressed its inner-day volatility in the short-term, which is inconsistent with most investigations. This phenomenon may be due to the fact that investors were more concerned about the withdrawal of monetary easing and fiscal stimulus, which were introduced to fight against the epidemic's impact on economy, than the epidemic itself. This study complements the limitations of most existing studies, which just focus on the period of the epidemic's outbreak, and provides insight into macroeconomic policy making in the era of the post COVID-19 epidemic such as the structural and ordered exit of the stimulating policies, intervention in IBOLR and balance social and economic sustainability.

The Impact of COVID-19 Pandemic on the Effectiveness of the CAPM Model: Evidence from the Chinese Market and Pharmaceutical Industry

Research on Chinese stock market based on CAPM: pre and post Covid-19 pandemic

A Study of the Impact of COVID-19 on the Chinese Stock Market Based on a New Textual Multiple ARMA Model

Differences between Chinese and U.S. Stock Markets in the Post-Pandemic Era: Fama Statistics and Application of the French Model

The influence of the SARS pandemic on asset prices

Analysis of Capital Asset Pricing Model in Chinese Stock Market

Does China’s Stock Market React to COVID-19 Differently at Industry Level? Evidence from China

An Empirical Study of Capital Asset Pricing Model based on Chinese A-share Trading Data

Applicability Analysis of CAPM Model in the Context of Epidemic

“ Risk Factors and Asset Pricing : Evidence from China ’ s A-Share Market ” 1

Do Investors Repeat History: Evidence from Post-pandemic Pharmaceuticals Industry

Stocks Vote with Their Feet: Can a Piece of Paper Document Fights the COVID-19 Pandemic?

The Applicability of Classic Capital Asset Pricing Model in Chinese Stock Market

The Research on the Application of CAPM Model in Chinese Stock Market

Application and Empirical Analysis of Asset Pricing Models in the Chinese Stock Market

Impact of the COVID-19 Pandemic on China's Stock Market Volatility, During and After the Outbreak: Evidence From an ARDL Approach

The Impact of the Coronavirus Disease 2019 Pandemic on Investor Sentiment-Evidence From A-Share Listed Companies in China

Pandemic or panic? A firm-level study on the psychological and industrial impacts of COVID-19 on the Chinese stock market

Covid-19’s effect on the alpha and beta of a US stock Exchange Traded Fund

COVID-19 and financial market response in China: Micro evidence and possible mechanisms

The Impact of COVID-19 on Stock Markets